Unlike allopurinol,
ELITEK® (rasburicase) clears new and existing uric acid1

ELITEK is the only antihyperuricemic agent that has the mechanism to clear existing uric acid1

  • Allopurinol blocks the formation of new uric acid but has no mechanism to clear uric acid1
Mechanism of action: ELITEK vs allopurinol1,2

ELITEK clears new and existing uric acid; allopurinol only blocks formation of new uric acid

ELITEK clears new and existing uric acid; allopurinol only blocks formation of new uric acid

Green background

Consider ELITEK as your preferred choice for clearing both existing and newly formed uric acid1

Mechanism of action (MOA) Flashcard

Reference this MOA flashcard for an overview of how ELITEK works

DOWNLOAD NOW

ELITEK significantly and rapidly lowered uric acid levels compared with allopurinol3,4

96%

of adult patients who received ELITEK achieved uric acid levels ≤2 mg/dL within 4 hours after their first dose vs 0% with allopurinol
Reduction in uric acid levels

96%

of adult patients who received ELITEK achieved uric acid levels ≤2 mg/dL within 4 hours after their first dose vs 0% with allopurinol

ELITEK clinical data

*Plasma uric acid AUC from Day 1 through Day 7 was significantly lower for ELITEK and ELITEK + allopurinol than for allopurinol alone.

 

VIEW ELITEK DOSING

References: 1. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275-279. 2. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778. 3. ELITEK [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 4. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.